TWST

MKT CAP:$4B

Twist Bioscience Corporation

Market Cap

$4B

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$59.10+$26.71 (+82.48%)

Apr 23, 2026

Company Details

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synt...

CEO

Emily Marine Leproust

IPO Date

Oct 31, 2018

Website

www.twistbioscience.com

Key Metrics TTM

Revenue

$392M

+18.6% YoY

Net Income

-$77M

EPS (Diluted)

-$1.28

Free Cash Flow

-$87M

Revenue / Share

$6.41

Gross Margin

51.6%

Operating Margin

-34.4%

Net Margin

-19.6%

FCF Margin

-22.1%

P/S

9.5x

P/E

—

Earnings Reports

Q2 2026

May 4, 2026

PENDING

Q1 2026

Feb 2, 2026

$104M+16.9%EPS -$0.50

FY 2025

Nov 17, 2025

$377M+20.3%EPS -$1.30

Q4 2025

Nov 17, 2025

$99M+16.9%EPS -$0.45

Q3 2025

Aug 4, 2025

$96M+17.9%EPS $0.33

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$48M	$18M	-$61M
Q3 22	$56M	$25M	-$61M
Q4 22	$57M	$26M	-$57M
Q1 23	$54M	$25M	-$45M
Q2 23	$60M	$19M	-$62M
Q3 23	$64M	$22M	-$61M
Q4 23	$67M	$25M	-$50M
Q1 24	$71M	$29M	-$47M
Q2 24	$75M	$31M	-$49M
Q3 24	$81M	$35M	-$89M
Q4 24	$85M	$38M	-$36M
Q1 25	$89M	$43M	-$35M
Q2 25	$93M	$46M	-$42M
Q3 25	$96M	$51M	-$30M
Q4 25	$99M	$51M	-$30M
Q1 26	$104M	$54M	-$33M

Valuation

Quarter	P/S	P/E
Q2 22	22.8x	—
Q3 22	20.2x	—
Q4 22	18.3x	—
Q1 23	17.3x	—
Q2 23	16.3x	—
Q3 23	15.8x	—
Q4 23	15.2x	—
Q1 24	14.2x	—
Q2 24	13.4x	—
Q3 24	12.6x	—
Q4 24	11.9x	—
Q1 25	11.3x	—
Q2 25	10.7x	—
Q3 25	10.3x	—
Q4 25	9.9x	—
Q1 26	9.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	-$42M	-$74M
Q3 22	-$34M	-$75M
Q4 22	-$1M	-$18M
Q1 23	-$54M	-$66M
Q2 23	-$44M	-$53M
Q3 23	-$23M	-$28M
Q4 23	-$21M	-$23M
Q1 24	-$23M	-$24M
Q2 24	-$19M	-$20M
Q3 24	-$6M	-$7M
Q4 24	-$15M	-$17M
Q1 25	-$21M	-$24M
Q2 25	-$13M	-$17M
Q3 25	-$1M	-$11M
Q4 25	-$12M	-$24M
Q1 26	-$25M	-$35M

Capital Expenditures

Quarter	CapEx
Q2 22	$32M
Q3 22	$41M
Q4 22	$16M
Q1 23	$12M
Q2 23	$9M
Q3 23	$5M
Q4 23	$2M
Q1 24	$2M
Q2 24	$603.0K
Q3 24	$965.0K
Q4 24	$2M
Q1 25	$2M
Q2 25	$4M
Q3 25	$9M
Q4 25	$12M
Q1 26	$10M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+54.2%	+57.4%
Q3 22	+60.2%	+52.0%
Q4 22	+51.0%	+46.8%
Q1 23	+29.1%	+0.9%
Q2 23	+25.0%	+11.8%
Q3 23	+13.6%	+6.2%
Q4 23	+16.8%	+2.5%
Q1 24	+31.8%	+19.8%
Q2 24	+25.1%	+1.9%
Q3 24	+27.8%	+36.8%
Q4 24	+26.5%	+3.2%
Q1 25	+24.1%	+4.1%
Q2 25	+23.2%	+8.2%
Q3 25	+17.9%	-25.9%
Q4 25	+16.9%	+6.8%
Q1 26	+16.9%	+10.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$22M	46.7%
Q3 22	$20M	35.7%
Q4 22	$19M	33.2%
Q1 23	-$2M	-4.3%
Q2 23	$10M	17.0%
Q3 23	$11M	16.6%
Q4 23	$12M	17.5%
Q1 24	$11M	15.4%
Q2 24	$14M	18.4%
Q3 24	$14M	16.9%
Q4 24	$12M	14.6%
Q1 25	$12M	13.5%
Q2 25	$20M	21.9%
Q3 25	$16M	16.7%
Q4 25	$16M	16.2%
Q1 26	$13M	12.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 22	$31M	—	—	$54M
Q3 22	$37M	—	—	$54M
Q4 22	$30M	—	—	$54M
Q1 23	$31M	—	—	$42M
Q2 23	$27M	—	—	$54M
Q3 23	$25M	—	—	$46M
Q4 23	$24M	—	—	$47M
Q1 24	$23M	—	—	$53M
Q2 24	$24M	—	—	$56M
Q3 24	$22M	—	—	$57M
Q4 24	$21M	—	—	$53M
Q1 25	$21M	—	—	$56M
Q2 25	$24M	—	—	$64M
Q3 25	$18M	—	—	$63M
Q4 25	$17M	$57M	$7M	—
Q1 26	$17M	—	—	$70M

Revenue Segments

Quarter	Antibody Discovery	Dna And Biopharma Libraries	Ngs Tools	Oligo Pools	Synthetic Genes
Q2 22	$7M	$2M	$23M	$2M	$14M
Q3 22	$6M	$1M	$28M	$3M	$17M
Q4 22	$7M	$1M	$29M	$4M	$16M
Q1 23	$8M	$2M	$24M	$4M	$16M
Q2 23	$7M	$3M	$29M	$3M	$18M
Q3 23	$5M	$3M	$33M	$4M	$19M
Q4 23	$3M	$3M	$37M	$4M	$20M
Q1 24	$5M	$3M	$39M	$4M	$20M
Q2 24	$5M	$4M	$41M	$4M	$22M
Q3 24	$5M	$4M	$43M	$4M	$25M
Q4 24	$5M	$4M	$46M	$5M	$26M
Q1 25	$6M	$3M	$49M	$5M	$26M
Q2 25	$6M	$3M	$51M	$5M	$28M
Q3 25	$6M	$2M	$55M	$5M	$28M
Q4 25	$6M	$3M	$53M	$5M	$31M
Q1 26	$51M	—	$53M	—	—

Revenue by Geography

Quarter	Americas	Asia Pacific	Emea
Q2 22	$28M	$4M	$15M
Q3 22	$36M	$5M	$15M
Q4 22	$35M	$6M	$17M
Q1 23	$34M	$4M	$16M
Q2 23	$35M	$6M	$19M
Q3 23	$39M	$6M	$19M
Q4 23	$44M	$6M	$17M
Q1 24	$44M	$6M	$21M
Q2 24	$46M	$7M	$22M
Q3 24	$51M	$6M	$24M
Q4 24	$53M	$7M	$26M
Q1 25	$54M	$7M	$28M
Q2 25	$55M	$7M	$31M
Q3 25	$59M	$6M	$31M
Q4 25	$57M	$7M	$35M
Q1 26	$58M	$7M	$38M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$408M	$166M	$574M
Q3 22	$376M	$151M	$528M
Q4 22	$379M	$126M	$505M
Q1 23	$317M	$122M	$439M
Q2 23	$315M	$72M	$388M
Q3 23	$307M	$50M	$357M
Q4 23	$286M	$50M	$336M
Q1 24	$266M	$45M	$311M
Q2 24	$243M	$50M	$293M
Q3 24	$239M	$50M	$289M
Q4 24	$226M	$50M	$276M
Q1 25	$221M	$49M	$271M
Q2 25	$210M	$47M	$257M
Q3 25	$201M	$49M	$251M
Q4 25	$183M	$49M	$232M
Q1 26	$149M	$49M	$198M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	53M	+7.1%	+9.8%
Q3 22	56M	+5.3%	+15.0%
Q4 22	56M	-0.0%	+14.0%
Q1 23	56M	+0.3%	+13.1%
Q2 23	57M	+0.6%	+6.2%
Q3 23	57M	+0.5%	+1.3%
Q4 23	57M	+0.4%	+1.8%
Q1 24	57M	+0.4%	+1.9%
Q2 24	58M	+0.5%	+1.8%
Q3 24	58M	+0.6%	+1.9%
Q4 24	58M	-0.2%	+1.3%
Q1 25	59M	+2.0%	+2.9%
Q2 25	60M	+0.8%	+3.2%
Q3 25	61M	+2.5%	+5.2%
Q4 25	60M	-1.2%	+4.2%
Q1 26	61M	+1.1%	+3.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$73.8K	652
Q3 22	$86.1K	652
Q4 22	$57.9K	989
Q1 23	$54.8K	989
Q2 23	$60.8K	989
Q3 23	$64.4K	989
Q4 23	$72.8K	919
Q1 24	$77.8K	919
Q2 24	$81.9K	919
Q3 24	$88.6K	919
Q4 24	$91.8K	923
Q1 25	$96.1K	923
Q2 25	$100.5K	923
Q3 25	$104.1K	923
Q4 25	$101.1K	979
Q1 26	$105.9K	979

Revenue / Employee